GEHC
GE HealthCare Technologies Inc. NASDAQ Listed Dec 15, 2022$61.59
+0.72%
vs $61.15
Mkt Cap $28.3B
52w Low $59.49
7.3% of range
52w High $88.16
50d MA $65.40
200d MA $74.64
P/E (TTM)
13.5x
EV/EBITDA
8.8x
P/B
2.6x
Debt/Equity
1.0x
ROE
17.9%
P/FCF
18.8x
RSI (14)
47.20
ATR (14)
$1.80
Beta
1.31
50d MA
$65.40
200d MA
$74.64
Avg Volume
4.9M
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, Hong Kong, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, and X-ray systems, as well as women's health products. The Ultrasound segment provides screening, diagnosis, treatment, and monitoring of certain diseases through radiology and primary care, women's health, cardiovascular, and point of care and handheld ultrasound solutions, as well as surgical visualization and guidance products. The Patient Care Solutions segment involved in the provision of medical devices, consumable products, services, and digital solutions through patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal infant care products. The Pharmaceutical Diagnostics supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, positron emission tomography, and ultrasound to the radiology and nuclear medicine industry. The segment also provides contrast media pharmaceuticals, administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents, or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes that are injected into a patient prior to a diagnostic imaging scan. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.
500 West Monroe Street · Chicago, IL 60661 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 29, 2026 | TNS | 1.07 | 0.99 | -7.5% | 59.49 | -0.5% | +2.3% | +0.3% | -0.0% | +0.1% | +1.1% | — |
| Feb 4, 2026 | TNS | 1.40 | 1.44 | +2.9% | 82.63 | -0.4% | -0.4% | -2.0% | -1.9% | +0.2% | -0.0% | — |
| Oct 29, 2025 | TNS | 1.05 | 1.07 | +1.9% | 77.38 | +0.0% | -3.1% | -0.1% | -0.6% | -0.2% | +1.8% | — |
| Jul 30, 2025 | TNS | 0.92 | 1.06 | +15.5% | 71.64 | +1.0% | -0.4% | -2.1% | +1.1% | +0.1% | -1.1% | — |
| Apr 30, 2025 | TNS | 0.91 | 1.01 | +10.5% | 70.33 | -0.0% | -3.8% | +4.2% | -1.6% | -3.3% | +2.6% | — |
| Feb 13, 2025 | TNS | 1.26 | 1.45 | +15.1% | 93.48 | -0.3% | -1.4% | +0.5% | -0.2% | -0.5% | -1.1% | — |
| Oct 30, 2024 | TNS | 1.05 | 1.14 | +8.6% | 87.20 | -1.2% | +0.2% | -0.5% | +0.0% | +1.4% | -1.6% | — |
| Jul 31, 2024 | TNS | 0.98 | 1.00 | +2.0% | 84.63 | -0.6% | -1.5% | +0.0% | -2.3% | +0.0% | -2.7% | — |
| Apr 30, 2024 | TNS | 0.91 | 0.90 | -1.1% | 76.24 | +0.4% | +2.6% | -0.5% | +2.1% | +0.4% | +2.0% | — |
| Feb 6, 2024 | TNS | 1.07 | 1.18 | +10.3% | 81.96 | +0.1% | -0.2% | +0.3% | -0.9% | +2.2% | -1.0% | — |
| Oct 31, 2023 | TNS | 0.90 | 0.99 | +10.0% | 66.57 | +0.3% | +2.6% | +1.4% | +3.4% | -0.7% | -0.5% | — |
| Jul 25, 2023 | TNS | 0.87 | 0.92 | +5.7% | 80.21 | +0.1% | -3.5% | -0.7% | +1.3% | +0.2% | -0.4% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 21 | UBS | Upgrade | Sell → Neutral | $69 | $64.26 | $64.20 | -0.1% | +0.1% | -0.2% | -0.1% | -0.5% | -1.6% |
| Apr 30 | JP Morgan | Maintains | Neutral → Neutral | — | $59.49 | $59.21 | -0.5% | +2.3% | +0.3% | -0.0% | +0.1% | +1.1% |
| Apr 30 | Wells Fargo | Maintains | Overweight → Overweight | — | $59.49 | $59.21 | -0.5% | +2.3% | +0.3% | -0.0% | +0.1% | +1.1% |
| Apr 30 | Goldman Sachs | Downgrade | Buy → Neutral | $65 | $59.49 | $59.21 | -0.5% | +2.3% | +0.3% | -0.0% | +0.1% | +1.1% |
| Apr 30 | Evercore ISI | Maintains | Outperform → Outperform | — | $59.49 | $59.21 | -0.5% | +2.3% | +0.3% | -0.0% | +0.1% | +1.1% |
| Apr 30 | Citigroup | Maintains | Neutral → Neutral | — | $59.49 | $59.21 | -0.5% | +2.3% | +0.3% | -0.0% | +0.1% | +1.1% |
| Apr 30 | Barclays | Maintains | Equal Weight → Equal Weight | — | $59.49 | $59.21 | -0.5% | +2.3% | +0.3% | -0.0% | +0.1% | +1.1% |
| Apr 29 | BTIG | Maintains | Buy → Buy | — | $68.50 | $62.15 | -9.3% | -13.2% | +2.3% | +0.3% | -0.0% | +0.1% |
| Apr 21 | BTIG | Maintains | Buy → Buy | — | $74.15 | $74.43 | +0.4% | -2.5% | -1.2% | -2.1% | -1.5% | +2.4% |
| Apr 17 | Piper Sandler | Maintains | Overweight → Overweight | — | $73.20 | $75.04 | +2.5% | +2.0% | -0.7% | -2.5% | -1.2% | -2.1% |
| Apr 13 | Mizuho | Maintains | Outperform → Outperform | — | $73.18 | $72.62 | -0.8% | +0.9% | +1.1% | -1.6% | -0.4% | +2.0% |
| Apr 9 | Goldman Sachs | Maintains | Buy → Buy | — | $73.75 | $72.74 | -1.4% | -1.1% | +0.4% | +0.9% | +1.1% | -1.6% |
| Apr 6 | Evercore ISI | Maintains | Outperform → Outperform | — | $70.35 | $70.35 | +0.0% | +0.1% | -1.0% | +5.8% | -1.1% | +0.4% |
| Mar 26 | Piper Sandler | Maintains | Overweight → Overweight | — | $72.20 | $71.76 | -0.6% | -0.9% | -3.2% | -0.7% | +3.5% | +1.1% |
| Mar 19 | BTIG | Maintains | Buy → Buy | — | $70.25 | $69.44 | -1.2% | +0.2% | -1.0% | +2.9% | -1.0% | +1.7% |
| Mar 11 | Citigroup | Maintains | Neutral → Neutral | — | $72.73 | $72.57 | -0.2% | -0.1% | -3.2% | +0.6% | +2.0% | +0.2% |
| Feb 9 | BTIG | Maintains | Buy → Buy | — | $80.65 | $80.00 | -0.8% | -1.9% | +0.2% | -0.0% | -0.7% | +2.1% |
| Feb 6 | Barclays | Maintains | Equal Weight → Equal Weight | — | $82.31 | $82.48 | +0.2% | -2.0% | -1.9% | +0.2% | -0.0% | -0.7% |
| Feb 5 | Stifel | Maintains | Buy → Buy | — | $82.63 | $82.32 | -0.4% | -0.4% | -2.0% | -1.9% | +0.2% | -0.0% |
| Feb 5 | Wells Fargo | Maintains | Overweight → Overweight | — | $82.63 | $82.32 | -0.4% | -0.4% | -2.0% | -1.9% | +0.2% | -0.0% |
| Feb 5 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $82.63 | $82.32 | -0.4% | -0.4% | -2.0% | -1.9% | +0.2% | -0.0% |
| Feb 5 | Evercore ISI | Maintains | Outperform → Outperform | — | $82.63 | $82.32 | -0.4% | -0.4% | -2.0% | -1.9% | +0.2% | -0.0% |
| Feb 4 | BTIG | Maintains | Buy → Buy | — | $78.78 | $79.71 | +1.2% | +4.9% | -0.4% | -2.0% | -1.9% | +0.2% |
| Jan 30 | Piper Sandler | Maintains | Overweight → Overweight | — | $78.78 | $78.66 | -0.2% | +0.2% | +1.4% | -1.7% | +4.9% | -0.4% |
| Jan 15 | UBS | Downgrade | Neutral → Sell | — | $85.30 | $84.21 | -1.3% | -3.3% | -0.9% | -3.6% | +2.9% | +1.0% |
| Jan 7 | Stifel | Maintains | Buy → Buy | — | $86.73 | $86.33 | -0.5% | -1.1% | +2.8% | -1.0% | -0.4% | -2.5% |
| Jan 5 | BofA Securities | Maintains | Neutral → Neutral | — | $82.82 | $82.79 | -0.0% | +2.7% | +2.0% | -1.1% | +2.8% | -1.0% |
| Dec 11 | Citigroup | Maintains | Neutral → Neutral | — | $84.47 | $84.47 | +0.0% | +1.9% | -2.4% | +0.6% | -2.6% | +0.2% |
| Dec 11 | Jefferies | Maintains | Buy → Buy | — | $84.47 | $84.47 | +0.0% | +1.9% | -2.4% | +0.6% | -2.6% | +0.2% |
| Nov 21 | BTIG | Maintains | Buy → Buy | — | $74.75 | $74.89 | +0.2% | +2.3% | +2.3% | +2.2% | +0.8% | -0.8% |
| Oct 30 | Wells Fargo | Maintains | Overweight → Overweight | — | $77.38 | $77.38 | +0.0% | -3.1% | -0.1% | -0.6% | -0.2% | +1.8% |
| Oct 30 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $77.38 | $77.38 | +0.0% | -3.1% | -0.1% | -0.6% | -0.2% | +1.8% |
| Oct 30 | Evercore ISI | Maintains | Outperform → Outperform | — | $77.38 | $77.38 | +0.0% | -3.1% | -0.1% | -0.6% | -0.2% | +1.8% |
| Oct 13 | BTIG | Maintains | Buy → Buy | — | $71.01 | $72.02 | +1.4% | +1.2% | +0.7% | +1.2% | +0.2% | +0.9% |
| Oct 7 | Citigroup | Downgrade | Buy → Neutral | — | $76.41 | $75.13 | -1.7% | -2.5% | +0.9% | -1.2% | -4.3% | +1.2% |
| Jul 31 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $71.64 | $72.34 | +1.0% | -0.4% | -2.1% | +1.1% | +0.1% | -1.1% |
| Jul 31 | Citigroup | Maintains | Buy → Buy | — | $71.64 | $72.34 | +1.0% | -0.4% | -2.1% | +1.1% | +0.1% | -1.1% |
| Jul 9 | Citigroup | Maintains | Buy → Buy | — | $75.20 | $75.85 | +0.9% | +0.4% | +1.3% | -1.8% | -0.9% | -0.1% |
| May 6 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $69.37 | $68.48 | -1.3% | -3.3% | +2.6% | +2.4% | -0.9% | +6.1% |
| May 5 | UBS | Upgrade | Sell → Neutral | — | $70.53 | $69.93 | -0.9% | -1.6% | -3.3% | +2.6% | +2.4% | -0.9% |
| May 1 | Goldman Sachs | Maintains | Buy → Buy | — | $70.33 | $70.32 | -0.0% | -3.8% | +4.2% | -1.6% | -3.3% | +2.6% |
| May 1 | Evercore ISI | Maintains | Outperform → Outperform | — | $70.33 | $70.32 | -0.0% | -3.8% | +4.2% | -1.6% | -3.3% | +2.6% |
| May 1 | Wells Fargo | Maintains | Overweight → Overweight | — | $70.33 | $70.32 | -0.0% | -3.8% | +4.2% | -1.6% | -3.3% | +2.6% |
| Apr 30 | Citigroup | Maintains | Buy → Buy | — | $68.09 | $72.50 | +6.5% | +3.3% | -3.8% | +4.2% | -1.6% | -3.3% |
| Apr 23 | Piper Sandler | Maintains | Overweight → Overweight | — | $61.65 | $64.50 | +4.6% | +5.3% | +3.4% | +2.0% | -0.5% | +0.0% |
| Mar 11 | Goldman Sachs | Upgrade | Neutral → Buy | — | $85.36 | $87.34 | +2.3% | +0.3% | -2.1% | -2.8% | +0.6% | +0.6% |
| Feb 14 | Wells Fargo | Maintains | Overweight → Overweight | — | $93.48 | $93.20 | -0.3% | -1.4% | +0.5% | -0.2% | -0.5% | -1.1% |
| Feb 13 | Citigroup | Maintains | Buy → Buy | — | $85.90 | $90.00 | +4.8% | +8.8% | -1.4% | +0.5% | -0.2% | -0.5% |
| Jan 8 | Jefferies | Upgrade | Hold → Buy | — | $83.37 | $84.65 | +1.5% | +3.5% | -1.7% | +0.7% | -1.4% | -0.6% |
| Oct 31 | Wells Fargo | Maintains | Overweight → Overweight | — | $87.20 | $86.12 | -1.2% | +0.2% | -0.5% | +0.0% | +1.4% | -1.6% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 22, 2026 | Lobo KevinDir | — | Buy | 10,000 | $64.18 | $642K | 14,363 | -0.47% | -1.12% |
| May 12, 2026 | Hochman Rodney FDir | — | Buy | 1,618 | $62.03 | $100K | 1,618 | +1.26% | +4.35% |
| May 8, 2026 | Yang Watkin Phoebe L.Dir | — | Buy | 1,000 | $63.01 | $63K | 13,702 | +0.96% | +1.23% |
| May 6, 2026 | CULP H LAWRENCE JRDir | — | Buy | 80,805 | $61.88 | $5.0M | 151,207 | +3.47% | +1.26% |
| May 6, 2026 | Stromberg William JDir | — | Buy | 1,000 | $61.69 | $62K | 15,330 | +3.47% | +1.26% |
| May 1, 2026 | SACCARO JAMESOff | Chief Financial Officer | Buy | 3,310 | $60.60 | $201K | 87,471 | -0.05% | +3.47% |
| Apr 30, 2026 | Arduini Peter JDir/Off | President and CEO | Buy | 4,169 | $59.92 | $250K | 259,424 | +0.31% | -0.65% |
| Apr 30, 2026 | Jimenez Frank ROff | GC & Corporate Secretary | Buy | 1,750 | $60.45 | $106K | 93,932 | +0.31% | -0.65% |
8-K
GE HealthCare Technologies Inc. -- 8-K Filing
GE HealthCare exceeded topline expectations at year-start, with strong growth in Pharmaceutical Diagnostics, Advanced Visualization, and Imaging segments driving performance.
Apr 29
8-K
Unknown — 8-K Filing
I cannot provide meaningful analysis from this filing summary, as it contains only technical XBRL metadata and XML schema references without actual business substance or financial information relevant to GEHC or PH stock performance.
Mar 17
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Kevin A.'s appointment as CEO following Mihaljevic's departure creates leadership uncertainty at GE Healthcare, potentially pressuring the stock until investors assess the new leader's strategic vision and execution capability.
Mar 17
8-K · 1.01
! Medium
GE HealthCare Technologies Inc. -- 8-K 1.01: Financing / Debt Agreement
GE HealthCare replaced its $500 million 364-day revolving credit facility with a new agreement maturing February 2027, providing continued liquidity access through JPMorgan Chase Bank.
Feb 27
8-K
GE HealthCare Technologies Inc. -- 8-K Filing
GE HealthCare exceeded Q4 2025 revenue and EPS expectations with 7.1% total revenue growth and 4.8% organic growth, demonstrating operational momentum as a standalone public company.
Feb 4
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Dodge & Cox | 31,312,064 | $2.2B | — | Mar 2026 |
| 2 | Vanguard Capital Management Llc | 28,864,188 | $2.1B | New | Mar 2026 |
| 3 | Capital Research Global Investors | 21,108,753 | $1.5B | Reduced | Mar 2026 |
| 4 | Vanguard Portfolio Management Llc | 19,183,157 | $1.4B | New | Mar 2026 |
| 5 | Morgan Stanley | 13,775,286 | $1.1B | Reduced | Dec 2025 |
| 6 | Barrow Hanley Mewhinney & Strauss Llc | 11,884,588 | $846M | Added | Mar 2026 |
| 7 | Jpmorgan Chase & Co | 8,964,669 | $617M | Added | Mar 2026 |
| 8 | Invesco Ltd. | 7,738,308 | $551M | Added | Mar 2026 |
| 9 | Boston Partners | 5,097,700 | $363M | Added | Mar 2026 |
| 10 | Locust Wood Capital Advisers, Llc | 4,239,967 | $302M | Reduced | Mar 2026 |
| 11 | Bank Of America Corp /de/ | 4,132,740 | $294M | Reduced | Mar 2026 |
| 12 | Northern Trust Corp | 4,052,065 | $288M | Reduced | Mar 2026 |
| 13 | Temasek Holdings (Private) Ltd | 3,261,309 | $232M | Added | Mar 2026 |
| 14 | Bank Of New York Mellon Corp | 2,819,912 | $201M | Reduced | Mar 2026 |
| 15 | Ubs Group Ag | 2,805,315 | $200M | Reduced | Mar 2026 |
| 16 | Fmr Llc | 2,775,113 | $198M | Reduced | Mar 2026 |
| 17 | Barclays Plc | 1,818,661 | $129M | Added | Mar 2026 |
| 18 | Menora Mivtachim Holdings Ltd. | 1,715,250 | $122M | — | Mar 2026 |
| 19 | Royal Bank Of Canada | 1,451,507 | $103M | Reduced | Mar 2026 |
| 20 | Nordea Investment Management Ab | 1,401,293 | $97M | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Dodge & Cox Stock Fund | 21,100,966 | $1.5B | Mar 2026 |
| 2 | VANGUARD WINDSOR II FUND | 8,782,229 | $694M | Jan 2026 |
| 3 | Fidelity 500 Index Fund | 5,797,084 | $489M | Feb 2026 |
| 4 | iShares Core S&P 500 ETF | 5,861,809 | $417M | Mar 2026 |
| 5 | Capital Group Dividend Value ETF | 3,672,593 | $309M | Feb 2026 |
| 6 | Invesco S&P 500 Equal Weight ETF | 1,886,300 | $149M | Jan 2026 |
| 7 | Invesco NASDAQ 100 ETF | 1,732,964 | $146M | Feb 2026 |
| 8 | iShares U.S. Medical Devices ETF | 1,961,682 | $140M | Mar 2026 |
| 9 | iShares Russell Mid-Cap ETF | 1,750,407 | $125M | Mar 2026 |
| 10 | Dodge & Cox Balanced Fund | 1,628,000 | $116M | Mar 2026 |
| 11 | Dodge & Cox Global Stock Fund | 1,621,900 | $115M | Mar 2026 |
| 12 | THE U.S. LARGE CAP VALUE SERIES | 1,422,310 | $112M | Jan 2026 |
| 13 | JPMorgan Large Cap Value Fund | 1,204,390 | $86M | Mar 2026 |
| 14 | Invesco Comstock Fund | 1,041,535 | $82M | Jan 2026 |
| 15 | Schwab S&P 500 Index Fund | 1,020,996 | $81M | Jan 2026 |
| 16 | Fidelity Total Market Index Fund | 851,660 | $72M | Feb 2026 |
| 17 | State Street(R) SPDR(R) Portfolio S&P 500(R) ETF | 958,577 | $68M | Mar 2026 |
| 18 | Heritage Fund | 835,439 | $66M | Jan 2026 |
| 19 | Fidelity Series Total Market Index Fund | 675,152 | $57M | Feb 2026 |
| 20 | iShares Core S&P Total U.S. Stock Market ETF | 572,192 | $41M | Mar 2026 |
Valuation
Market Cap
$28.35B
Enterprise Value
$33.33B
P/E (TTM)
13.54x
Forward P/E
12.45x
PEG Ratio
4.13x
P/B
2.65x
P/S
1.37x
P/FCF
18.82x
EV/EBITDA
8.81x
Shares Out
460.3M
Financials (TTM)
Revenue
$20.62B
Net Income
$2.08B
EBITDA
$3.79B
Free Cash Flow
$1.51B
Op Cash Flow
$1.99B
EPS Basic
$4.56
EPS Diluted
$4.55
EPS Forward
$4.95
Gross Margin
40.0%
Op Margin
13.4%
Net Margin
10.1%
Balance Sheet
Total Assets
$36.91B
Total Liab.
$26.31B
Total Equity
$10.60B
Cash
$4.51B
LT Debt
$9.49B
Book Value/Sh
$23.22
Debt/Equity
0.96x
Current Ratio
1.18
Quick Ratio
0.93
Returns & Growth
ROE
17.9%
ROA
5.1%
ROIC
8.8%
Rev Growth YoY
+4.8%
EPS Growth YoY
+4.3%
Price Returns
2W
-0.5%
1M
+2.5%
3M
-26.0%
6M
-22.1%
12M
-11.6%
Technicals
52W High
$88.16
52W Low
$59.49
50d MA
$65.40
200d MA
$74.64
RSI (14)
47.20
ATR (14)
$1.80
Beta
1.31
Avg Volume
4.9M
Dividends
Div Rate
$0.14
Div Yield
0.2%
Frequency
4
Ex-Div Date
Apr 2, 2026
Analyst Price Targets
Consensus
$84.00
High
$105.00
Low
$65.00
Median
$85.00
Data updated apr 25, 2026 11:06am
· Source: financialmodelingprep.com